<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00873353</url>
  </required_header>
  <id_info>
    <org_study_id>ML21154</org_study_id>
    <secondary_id>2007-003206-96</secondary_id>
    <nct_id>NCT00873353</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients</brief_title>
  <acronym>XELTA</acronym>
  <official_title>An Open Non-randomized Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Tarceva in Combination With Capecitabine in Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Gallego de Investigaciones Oncologicas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Gallego de Investigaciones Oncologicas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of the treatment with erlotinib in
      combination with capecitabine in patients with advanced pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This efficacy will be determined by objective response rate following RECIST criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate following RECIST criteria</measure>
    <time_frame>within study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>within study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 months survival rate</measure>
    <time_frame>within first 6 months after study inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Time from study inclusion to disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>Time from study inclusion to treatment failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the index of clinical benefit</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of erlotinib and capecitabine when administered together</measure>
    <time_frame>Within study period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Metastatic Adenocarcinoma of the Pancreas</condition>
  <arm_group>
    <arm_group_label>Unique arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles (3 weeks each one) of :
capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks
erlotinib (Tarceva®) 150mg/day, oral. Days: every days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine + erlotinib</intervention_name>
    <description>6 cycles (3 weeks each one) of :
capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks
erlotinib (Tarceva®) 150mg/day, oral. Days: every days</description>
    <arm_group_label>Unique arm</arm_group_label>
    <other_name>capecitabine (Xeloda®)y erlotinib (Tarceva®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and willingness to sign a written informed consent

          2. Informed consent signed by the patient

          3. Age &gt; 18 years old

          4. Able to fulfill all criteria from the protocol

          5. Performance status Karnofsky ≥ 60% (ECOG 0-2)

          6. Life expectancy ≥ 12 weeks

          7. Histologically or cytological (excluding endocrine pancreatic tumour), with metastatic
             (stage IV), following 6th edition of TNM classification

          8. Measurable disease following RECIST criteria

          9. Adequate bone marrow function as determined by:

               -  Absolute Neutrophil account (ANC) ≥ 1,5 x 109/L

               -  Platelets: ≥ 100 x 109/L

               -  Hemoglobin: ≥ 9 g/dL.

         10. Adequate liver function, as determined by:

               -  Serum bilirubin (total): ≤ 1,5 x LSN

               -  AST, ALT ≤ 2,5 x LSN in patients without liver metastasis. In patients with liver
                  metastasis ≤ 5 x LSN

         11. Adequate renal function, as determined by:

               -  Clearance creatinine &gt; 60.0 ml/min

         12. Men or women potentially fertile (including postmenopausal women amenorrheic at least
             24 months before the study) should use adequate contraceptive methods (oral
             contraceptives, intrauterine disposal, barrier methods together with spermicide or
             surgery sterilization)

        Exclusion Criteria:

          1. Local pancreatic cancer (stage IA-IIB) or locally advance cancer (stage III),
             following the TNM 6th edition classification. Patients with metastatic disease that
             relapse after the initial diagnosis of local or advance disease could be included in
             this study.

          2. Evidence of medullary compression, carcinomatosis meningitis or brain metastasis. In
             case of clinical suspicious of brain metastasis is mandatory to perform a brain TAC/MR
             4 weeks prior inclusion.

          3. Previous systemic treatment for metastasis pancreas cancer. Adjuvant chemotherapy is
             permitted ≥ 4 weeks prior de inclusion. All toxicities from the adjuvant treatment
             must been solve before the inclusion and should be confirmed the diseases progression
             (metastatic disease) alter adjuvant treatment

          4. Primary tumours Developer 5 years previous to the inclusion, except in situ cérvix
             carcinoma or skin basocellular cancer properly treated

          5. Non-controlled hypertension or cardiovascular disease clinically significant (active):

               -  Cerebrovascular accident/ictus (≤ 6 weeks prior to inclusion)

               -  Heart attack (≤ 6 months prior to inclusion)

               -  Instable angina

               -  Congestive cardiac insufficiency (grade II or superior following to New York
                  Heart Association (NYHA)

               -  Severe cardiac arrhythmia that require medication

          6. Significant ophthalmology anomalies

          7. Deficit in dihydropyrimidine dehydrogenase (DPD)

          8. Unable to take oral drug. Previous surgical process that affect the absorption or make
             the needed to have intravenous feeding or parenteral nutrition with lipids.

          9. Pregnancy women or in latency period. Negative pregnancy test needed 7 days prior to
             initiation drug study

         10. Actual or 30 days previous to study treatment with other investigational drug or
             participation in other trial

         11. Previous treatment with Capecitabine or EGFR inhibitor.

         12. Any other disease, metabolic disease

         13. Known hypersensibility to any study drug or any of their component, or to
             5-fluorouracile
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafel López López, Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Grupo Gallego de Investigaciones Oncológicas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>La Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de La Coruña</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>La Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Xeral Calde</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Orense</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Xeral Cies</name>
      <address>
        <city>Vigo</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital POVISA</name>
      <address>
        <city>Vigo</city>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2009</study_first_posted>
  <last_update_submitted>August 17, 2010</last_update_submitted>
  <last_update_submitted_qc>August 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rafael López López</name_title>
    <organization>Grupo Gallego de Investigaciones Oncologicas</organization>
  </responsible_party>
  <keyword>Metastatic Adenocarcinoma of the Pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 12, 2015</submitted>
    <returned>March 25, 2015</returned>
    <submitted>February 22, 2016</submitted>
    <returned>March 21, 2016</returned>
    <submitted>March 29, 2016</submitted>
    <returned>April 29, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

